

FOLIA MEDICA CRACOVIENSIA

Vol. LX, 3, 2020: 5–16

PL ISSN 0015-5616

DOI: 10.24425/fmc.2020.135791

## Decreased number of regulatory T lymphocytes is related to inflammation and number of CD8<sup>+</sup> T cells expressing programmed cell death protein-1 in common variable immunodeficiency

EWELINA NOWAK<sup>1</sup>, JOANNA SULICKA-GRODZICKA<sup>2</sup>, MAGDALENA STRACH<sup>1</sup>,  
KAROLINA BUKOWSKA-STRAKOVA<sup>3</sup>, MACIEJ SIEDLAR<sup>3</sup>, MARIUSZ KORKOSZ<sup>2</sup>, TOMASZ GRODZICKI<sup>1</sup>

<sup>1</sup>Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Kraków, Poland

<sup>2</sup>Department of Rheumatology, Jagiellonian University Medical College, Kraków, Poland

<sup>3</sup>Department of Clinical Immunology, Institute of Pediatrics, Jagiellonian University Medical College, Kraków, Poland

**Corresponding author:** Joanna Sulicka-Grodzicka, M.D., Ph.D.  
Department of Rheumatology, Jagiellonian University Medical College  
ul. Jakubowskiego 2, 30-688 Kraków, Poland  
Phone: +48 12 400 31 00; E-mail: joanna.sulicka-grodzicka@uj.edu.pl

**Abstract:** Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder related to recurrent infections, as well as a range of non-infectious manifestations including autoimmune and inflammatory disorders. We hypothesized that patients with CVID and different clinical phenotypes would demonstrate alterations in lymphocyte T subsets, including T lymphocytes expressing programmed cell death protein 1 (PD-1), and regulatory T lymphocytes. We performed flow cytometry in two CVID groups: group 1 with infections only, and group 2 with infections and concomitant noninfectious manifestations. Patients were 18–59 years old (mean 35.8 years of age). Increased proportions of CD8<sup>+</sup>PD-1<sup>+</sup> T cells and reduced regulatory T cells were associated with lymphadenopathy. Amount of regulatory T cells correlated with CD8<sup>+</sup>PD-1<sup>+</sup> T lymphocytes ( $r = 0.54$ ;  $p = 0.013$ ), and with CRP ( $r = -0.64$ ;  $p = 0.004$ ). Forty percent of patients expressed manifestations in addition to infections (group 2), and they had reduction in number of regulatory T cells [8 (3–12) vs. 24 (11–26)/ $\mu$ l;  $p = 0.034$ ], naive CD4<sup>+</sup> T lymphocytes [36 (27–106) vs. 149 (81–283)/ $\mu$ l;  $p = 0.034$ ], and elevated C-reactive protein (CRP) [5.33 (3.15–8.82) vs. 1 (1–2.16) mg/l;  $p = 0.003$ ] in comparison to group 1. In conclusion, the amount of CD8<sup>+</sup> T cells expressing PD-1 is associated with lymphadenopathy and number of regulatory T cells in patients with CVID. Patients with CVID and non-infectious complications have increased level of inflammation and alterations in regulatory T cells.

**Keywords:** common variable immunodeficiency, T cells, regulatory T cells, PD-1/PD-Ls, chronic inflammation.

**Submitted:** 05-Nov-2020; **Accepted in the final form:** 16-Nov-2020; **Published:** 30-Nov-2020.

## Introduction

Common variable immunodeficiency disorder (CVID) is a primary immunodeficiency, a rare disease highly diverse in clinical manifestations, and characterized by hypogammaglobulinemia [1]. Although several monogenic forms of CVID have been described, the mode of inheritance is mostly polygenic [1, 2]. Clinical manifestations of CVID include primarily recurrent sinopulmonary infections, but patients may also present increased predisposition to development of cancer, autoimmunity or inflammatory disorders [1]. Autoimmune disorders are diagnosed in about 20–25% of CVID patients [3]. In a recent retrospective study of patients with PIDs by Fischer *et al.* [4], survival time was significantly shorter in subjects with autoimmune and/or inflammatory manifestations than in patients without these manifestations. Moreover, in that population the risk of autoimmune cytopenia was significantly higher in comparison with general population. In addition, in Fischer's report, inflammatory bowel disease and arthritis were among the most frequent autoimmune/inflammatory diseases and subjects with CVID and T-cell deficiencies demonstrated the highest risk [4]. Various mechanisms of immune dysregulation, abnormalities in both B and T lymphocytes leading to non-infectious complications in CVID have been proposed. For instance, mutations in the gene encoding nuclear factor  $\kappa$ B subunit 1 (NF- $\kappa$ B1), reduced NF- $\kappa$ B1 protein levels, and expanded CD21<sup>low</sup> B-cell subset have been demonstrated in patients with CVID and inflammatory bowel disease, arthritis or Behçet disease, compared with healthy controls subjects [5]. In addition, aberrations in T lymphocytes, including decreased CD4<sup>+</sup> lymphocytes, regulatory T cells, and Th17 cells have also been suggested, and were associated with lymphoproliferative complications in some studies [6–9]. To our best knowledge, the role of the programmed cell death protein 1 (PD-1) has not been extensively evaluated in CVID. PD-1 exerts a suppressive effect on self-reactive T cells, and may also be engaged in the suppression of effector T lymphocytes, and therefore may have negative effects on antiviral and anticancer response [10–12]. The purpose of our research, therefore, was to assess lymphocyte T subsets, including CD8<sup>+</sup>PD-1 and regulatory T lymphocytes in CVID patients in relation to clinical manifestations.

## Materials and Methods

The diagnosis of CVID was based on the European Society for Immunodeficiencies (ESID) criteria [13]. We enrolled 20 adult patients with CVID receiving regular immunoglobulin replacement therapy every 3 to 4 weeks. Patients were included in the study after informed written consent was obtained from each individual, the study was conducted according to the approval by the local institutional ethics committee and in accordance with the 1964 Helsinki declaration and its later amendments. None of the patients received immunosuppressive therapy other than a low dose of glucocorticoids

(less than or equal to 7.5 mg prednisone per day — 3 cases) at the time of the study and in 6 months prior the study. Data such as number of infections, concomitant diseases, IG dose, and age at diagnosis were collected retrospectively. Patients were divided into two clinical phenotypes: group 1 including patients diagnosed with CVID, and with infections as a principal clinical manifestation, and group 2 including patients with CVID, infections and associated inflammatory complications including gastrointestinal diseases (inflammatory bowel disease, celiac disease, primary biliary cholangitis), psoriasis, psoriatic arthritis, and diabetes type 1. Additionally, patients in group 2 had clinical manifestations including splenomegaly, lymphadenopathy, and cytopenias.

### *Laboratory studies*

All laboratory tests were performed on blood samples taken directly before consecutive IG administration, and basic tests included: complete blood count with differential, glucose, creatinine, alanine aminotransferase (ALT), asparaginian aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transpeptidase (GGTP), bilirubin, thyrotropin releasing hormone (TSH), total protein, albumin, iron, ferritin, total iron binding capacity (TIBC), IgG, IgA, IgM and C-reactive protein (CRP). An abdominal ultrasound exam was also performed to evaluate spleen size.

Peripheral blood samples were incubated with monoclonal fluorescent-antibodies in order to evaluate surface antigen expression among lymphocyte populations (including anti-CD3-FITC, anti-CD4-Alexa Fluor 700, anti-CD8-APC-H7, anti-CD25-PE, anti-CD27-BC510, anti-CD28-PerCP-Cy5.5, anti-CD127-BV605, anti-CD279-Alexa Fluor 647, anti-CD45RA-PE-Cy7, anti-HLA-DR-PerCP, anti-CCR7-BV421 obtained from BD Biosciences, San Jose, CA, USA) using flow cytometry. The samples were then treated with FACS Lysing Solution (BD), washed twice with PBS, handled in the FACSCanto 10 color flow cytometer (Immunocytometry Systems, BD), and evaluated with FACSDiva Software (BD). The absolute numbers of lymphocyte subpopulations were determined applying dual-platform method. The absolute lymphocyte count was derived from a hematology cell analyzer ABX Micros ES 60 Horiba (Horiba Medical, Irvine, CA, USA). Lymphocytes were gated according to forward scatter (FSC) and side scatter (SSC) signals from PBMC and T cells were gated according to CD3 expression. Percentages and numbers of CD4 and CD8 positive subpopulations were assessed. T cell subpopulations were also analysed for the presence of naïve (N) T lymphocytes (CD45RA<sup>+</sup>CCR7<sup>+</sup>CD28<sup>+</sup>CD27<sup>+</sup>CD127<sup>+</sup>CD279<sup>-</sup>), effector memory (EM) T cells (CD45RA<sup>-</sup>CCR7<sup>-</sup>CD28<sup>+</sup>CD27<sup>+/-</sup>CD127<sup>+</sup>CD279<sup>+</sup>), central memory (CM) T cells (CD45RA<sup>-</sup>CCR7<sup>+</sup>CD27<sup>++</sup>CD28<sup>++</sup>CD127<sup>++</sup>CD279<sup>-</sup>), terminally differentiated effector memory (TEMRA) T cells (CD45RA<sup>+</sup>CCR7<sup>-</sup>CD27<sup>-</sup>CD28<sup>-</sup>CD127<sup>+</sup>CD279<sup>+/-</sup>), activated T cells (CD3/HLADR), and regulatory T cells (CD4<sup>+</sup>CD25<sup>++</sup>CD127<sup>-</sup>). PD-1 expression (CD279) was assessed on CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes.

## Statistical analyses

Results are presented as means (standard deviation, SD), medians (interquartile range, IQR) for continuous variables, and percentages for categorical variables. The conformity with a normal distribution was tested by the Kolmogorov–Smirnov test and uniformity of variances by Leven’s test. Intergroup differences were calculated applying the unpaired 2-sided Student’s t-test or Mann–Whitney U test, and Fisher’s exact test for continuous variables and proportions, respectively. Bivariate correlations between continuous variables were estimated by Spearman’s correlation coefficient ( $r$ ). All presented results were considered significant at  $p$  value below 0.05. Data were analyzed with Statsoft Statistica® software (statsoft Inc., STATISTICA data analysis software system, version 13).

## Results

The amount of patients included in the study was 20, with 11 (55%) males; aged 18–59 years. Mean age of diagnosis of CVID was  $27.5 \pm 15.5$  years, 7 patients were diagnosed before 15 years of age. Immunoglobulins were administered intravenously in 17 patients and subcutaneously in 3 patients, with an average dose of  $0.45 \pm 0.13$  g per kilogram of body weight. Among 20 patients, 12 (60%) presented with infections only (group 1), and 8 (40%) presented both with infections and other CVID associated noninfectious conditions (group 2), i.e. there were 5 cases of gastrointestinal inflammatory diseases, 1 case of primary biliary cholangitis, 1 case of diabetes type 1, and 1 case of psoriatic arthritis. Additionally, in group 2 any cytopenia was found in 8 subjects, lymphadenopathy and splenomegaly in 5 and 11 patients, respectively. Basic clinical findings are presented in Table 1 and Table 2. Patients from group 2 had significantly lower IgG serum levels despite comparable monthly IG dose, and elevated CRP levels as well as higher ALT and ALP levels compared with group 1.

**Table 1.** Clinical characteristics of CVID patients according to disease manifestations.

	Group 1 infections-only n = 12	Group 2 non-infectious complications n = 8	p
Age (years)	$33.5 \pm 13.1$	$39.1 \pm 12.3$	0.35
Age at CVID diagnosis (years)	$25.6 \pm 15.7$	$30.4 \pm 15.9$	0.51
Female sex (%)	50	37.5	0.67
Ig dose (g/kg)	$0.41 \pm 0.11$	$0.53 \pm 0.14$	<b>0.05</b>
IgG at diagnosis (g/l)	3.85 (1.44–5.24)	1.03 (0.37–2.8)	0.14
IgG (g/l)	$8.00 \pm 1.30$	$5.80 \pm 1.50$	<b>0.003</b>

IgA (g/l)	0.24 (0.24–0.25)	0.25 (0.24–0.22)	0.65
IgM (g/l)	0.28 (0.17–0.59)	0.17 (0.17–0.27)	0.34

Data are shown as the means  $\pm$  SD or the medians and the (25th and 75th) percentiles.

**Table 2.** Basic laboratory tests findings according to COVID manifestations.

	Group 1 infections-only n = 12	Group 2 non-infectious manifestations n = 8	p
CRP (mg/l)	1 (1–2.16)	5.33 (3.15–8.82)	0.003
Leukocytes ( $10^9/L$ )	5.87 $\pm$ 1.88	8.5 $\pm$ 4.53	0.23
Erythrocytes ( $10^{12}/L$ )	5.02 $\pm$ 0.44	4.8 $\pm$ 0.6	0.27
Haemoglobin (g/L)	138 $\pm$ 17	136 $\pm$ 18	0.71
Hematocrit (L/L)	0.41 $\pm$ 0.04	0.40 $\pm$ 0.04	0.51
Platelets ( $10^9/L$ )	210.5 $\pm$ 69.8	216.4 $\pm$ 153.4	0.48
Neutrophils ( $10^9/L$ )	3.07 $\pm$ 1.2	5.14 $\pm$ 2.91	0.09
Lymphocytes ( $10^9/L$ )	1.95 $\pm$ 0.8	2.45 $\pm$ 2.22	1
Monocytes ( $10^9/L$ )	0.63 $\pm$ 0.27	0.76 $\pm$ 0.5	0.77
AST (U/l)	25 (17–32)	29.5 (24.5–38.5)	0.25
ALT (U/l)	16 (13–29)	35 (32.5–51)	0.015
LDH (U/l)	358 $\pm$ 112.3	422.9 $\pm$ 140.2	0.17
GGTP (U/l)	11.5 (10–28)	21 (16–31)	0.30
ALP (U/l)	80.3	117.88	0.037
Glucose (mmol/l)	4.47 $\pm$ 0.63	5.2 $\pm$ 1.46	0.40
TSH (uIU/ml)	2.36 $\pm$ 1.09	2.25 $\pm$ 1.16	1
Creatinine ( $\mu$ mol/l)	64.7 $\pm$ 11.6	74.5 $\pm$ 34.5	0.79
CK (U/l)	112 (90–159)	64 (48–173)	0.24

Data are shown as the means  $\pm$  SD or the medians and the (25th and 75th) percentiles.


The results of the analysis of T lymphocyte subsets are presented in Table 3. White blood cell count and lymphocyte count were comparable in both groups. Within T lymphocytes, the number of naive CD4 T cells (median 447 cells/ $\mu$ l) and regulatory T cells (median 8 cells/ $\mu$ l) were substantially lower in group 2 in comparison to group 1 (median 679 cells/ $\mu$ l;  $p = 0.034$  and 24 cells/ $\mu$ l;  $p = 0.034$ ), respectively. Remaining T lymphocyte subsets, including numbers of T cells expressing PD-1 were comparable in both groups (Fig. 1).

**Table 3.** T cell subsets according to CVID manifestations.


	Group 1 infections-only n = 12	Group 2 non-infectious complications n = 8	p
Lymphocytes (/μl)	1850 (1300–2300)	1660 (1000–3250)	0.88
CD4 (/μl)	679 (409–906)	447 (314–881)	0.33
CD4 naive (/μl)	149 (81–283)	36 (27–106)	0.03
CD4 central memory (/μl)	110 (83–138)	80 (49–144)	0.46
CD4 effector memory (/μl)	63 ± 45	94 ± 72	0.30
CD4 TEMRA (/μl)	0.4 (0.1–4)	2 (0.2–9)	0.79
Regulatory T cells (/μl)	24 (11–26)	8 (3–12)	0.03
CD4 PD-1 (/μl)	240 ± 147	254 ± 117	0.82
CD8 (/μl)	613 (371–869)	952 (264–1553)	0.56
CD8 naive (/μl)	124 (56–160)	43 (11–119)	0.15
CD8 central memory (/μl)	30 (18–50)	26.8 (10.4–48.1)	0.96
CD8 effector memory (/μl)	17.8 (0.5–51.4)	20 (7–34)	0.91
CD8 TEMRA (/μl)	12 (6–20)	20 (7–26)	0.56
CD8 PD-1(/μl)	205 (133–341)	320 (133–341)	0.56

Data are shown as the means ± SD or the medians and the (25th and 75th) percentiles.


Splenomegaly was related to increased percentage of CD4<sup>+</sup> lymphocytes (49.5 ± 10.2 vs. 34.5 ± 11.8%; p = 0.007) and reduced percentage of CD8<sup>+</sup> lymphocytes (median 36.5 vs. 50.1%; p = 0.008). Lymphadenopathy, was related to elevated CRP level (median 7.02 vs. 1.62 mg/l; p = 0.02), lower percentage of naïve CD4<sup>+</sup> T cells (median 2.2 vs. 11.6%; p = 0.003), central memory CD4<sup>+</sup> lymphocytes (median 4.6 vs. 9.2%; p = 0.003), higher proportion of CD8<sup>+</sup> cells (66.4 ± 14.7 vs. 40.9 ± 9.0%; p <0.001), elevated percentage of CD8<sup>+</sup> lymphocytes expressing PD-1 (median 24 vs.14.1%; p = 0.001), and diminished proportion of regulatory T cells (0.5 vs. 1.2%; p = 0.009) (Fig. 2). Malignancy was confirmed in 1 patient (non-melanoma skin cancer). In the entire group of CVID patients, regulatory T cell number correlated negatively with CRP (r = -0,64; p = 0.004), and was positively associated with counts of CD8<sup>+</sup>PD-1<sup>+</sup> T lymphocytes (r = 0.54; p = 0.013), and CD4<sup>+</sup> naive T cells (r = 0.73; p <0.001) (Fig. 3).



**Fig. 1.** Comparison of T cells and subsets in two groups of COVID patients with non-infectious complications and infections-only. Representative plots with cells obtained from a COVID patient with disease associated complications (left panel a and b), and a COVID patient with infections only (right panel a and b) showing decreased number of regulatory T (Treg) cells (a), and naive CD4<sup>+</sup> T cells (b), comparable numbers of CD4<sup>+</sup>, CD8<sup>+</sup> and CD8<sup>+</sup> PD-1<sup>+</sup> T cells (c-e). Horizontal lines represent the medians. \*p < 0.05.



**Fig. 2.** Lymphadenopathy in COVID was associated with decreased percentage of regulatory T cells, naive CD4<sup>+</sup> T cells and increased proportion of CD8<sup>+</sup>PD-1<sup>+</sup> expressing T cells. Horizontal lines represent the medians. \*\*p < 0.01, \*\*\*p < 0.001.



**Fig. 3.** Reduced number of regulatory T cells in CVID correlated with decreased number of CD8<sup>+</sup>PD-1<sup>+</sup> T cells (a);  $p < 0.05$ , naive CD4<sup>+</sup> T cells (b);  $p < 0.001$ , and elevated C-reactive protein.

## Discussion

We have demonstrated the positive correlation among the number of CD8<sup>+</sup> T lymphocytes with PD-1 expression and regulatory T lymphocytes. We did not observe any substantial differences in PD-1 expression on T cell subsets between the infection-only group and the group with noninfectious complications, nonetheless we demonstrated that patients with lymphadenopathy had nearly 1.5 times increased proportion of CD8<sup>+</sup> T cells expressing PD-1 in comparison with patients without lymphadenopathy. Our research is one of a very small number of studies evaluating PD-1 expression on T cells in CVID. We believe that this is the first work, that shows presence of relation between regulatory T lymphocytes and CD8<sup>+</sup> lymphocytes expressing PD-1 in CVID. We have also demonstrated decreased counts of regulatory T lymphocytes and naive CD4<sup>+</sup> T lymphocytes, as well as increased C-reactive protein serum level in patients with CVID and concomitant noninfectious complications in comparison to the infection-only group. In addition, we showed that in the pooled groups low regulatory T lymphocytes correlated with increased C-reactive protein level.

The PD-1/PD-L pathway regulates peripheral tolerance and it is involved in tumor immunity and chronic infections [11, 12]. Our results are consistent with findings of Kuntz *et al.*, who found that CD8<sup>+</sup> T lymphocytes of patients with CVID demonstrated more antigen experienced and activated differentiation state, especially in a group with lymphadenopathy and granulomatous disease [14]. It has been confirmed that in chronic infections PD-1 could be used as a marker of exhausted CD8<sup>+</sup> T cells with impaired function [15], but CD8<sup>+</sup>PD-1<sup>+</sup> T cells are also found in healthy humans where PD-1 is a marker of the majority of effector memory T cells [16]. The mechanism of T cells exhaustion in CVID is not determined, but it may be related to chronic activation of CD8<sup>+</sup> T lymphocytes and prolonged expression of PD 1 caused by recurrent infections [17]. Marashi *et al.* found increased proportion of CMV CD8<sup>+</sup> T lymphocytes in CVID patients, and high levels of interferon- $\gamma$  and tumor necrosis factor- $\alpha$ , compared with healthy controls [18]. Autoimmunity may theoretically contribute to an excessive T cell response in CVID as well, although the role of autoimmunity is unproven [17]. The role of PD-1 in T lymphocyte impairment



has been studied in human with rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, myasthenia gravis or chronic hepatitis C infection [19–25]. In chronic inflammatory diseases, chronic stimulation of CD8<sup>+</sup> T cell could initiate exhaustion similar to that observed in chronic infections [25]. Nevertheless, a study by Petrelli *et al.* demonstrated that CD8<sup>+</sup> PD-1<sup>+</sup> lymphocytes in synovia of patients with juvenile idiopathic arthritis were effector lymphocytes and were not exhausted cells [26]. Therefore, according to these authors, PD-1<sup>+</sup> CD8<sup>+</sup> T cells could be antigen experienced lymphocytes specific to certain sites of chronic inflammation. Data on PD-1 in CVID is scarce. De Lollo *et al.* found enlarged expression of PD-1 on effector memory CD4<sup>+</sup> T lymphocytes compared to healthy individuals, but not on CD8<sup>+</sup> lymphocytes [27]. Another study demonstrated, that in CVID the functional impairment of CD4<sup>+</sup> T cells was caused by PD-1 associated cell exhaustion, and in vitro CD4 proliferation was brought back by blocking PD-L1/2 [28]. Noteworthy finding of our study is the association of CD8<sup>+</sup> lymphocytes expressing PD-1 with regulatory T cells in CVID. As regulatory T lymphocytes produce inhibitory cytokines such as interleukin-10 or transforming growth factor  $\beta$ , they may contribute to CD8<sup>+</sup> T lymphocyte exhaustion [29]. Furthermore, reduction of regulatory T cells and blockade of PD-1 has common effect on reversal of exhaustion of CD8<sup>+</sup> T cells [30]. Therefore, decreased expression of PD-1 in CVID, resulting in increased T cell proliferation and cytokine production may well impair immune responses and hasten autoimmunity, which is associated with decreased regulatory T cells.

The finding of decreased regulatory T cells in CVID is in line with the previously published data [31–33]. Observed changes in regulatory T cells in CVID may represent abnormal immune effects responsible for the phenomenon of autoimmunity [34]. Most of the studies evaluating the number and mechanisms of modulation of regulatory T cells function during inflammation refer to chronic inflammatory diseases, which also may occur in the course of CVID. The exception was a study by Fevang *et al.* performed in CVID patients, who showed that serum level of neopterin was correlated negatively with the amount of regulatory T cells [32]. A study by van Amelsfort *et al.* reported that the number of peripheral CD4<sup>+</sup>CD25<sup>++</sup> regulatory T lymphocytes in patients with rheumatoid arthritis was decreased as compared with the level found in their synovial fluid [35]. That phenomenon may be associated with the accumulation of regulatory T cells in tissues, and however not formally proven, it might be also relevant to the results of our study. The function of regulatory T cells may be varied in chronic inflammation, where impaired regulatory lymphocytes might contribute to activation of immune response and predispose to autoimmunity, as has been shown by Hguyen *et al.* [36].

We also found, that subjects with CVID and noninfectious complications presented additional T cell abnormalities, including decrease in naive CD4<sup>+</sup> T lymphocytes. The decline in naive CD4<sup>+</sup> T lymphocytes in CVID has been already described,

and it was shown to be associated with the severity of disease [37, 38], and with gastrointestinal symptoms or polyclonal lymphoproliferation [38]. Giovannetti *et al.* have previously classified CVID patients according to number of naive CD4<sup>+</sup> T lymphocytes, and the group with decreased number was characterized by T lymphocyte activation, proliferation, apoptosis, and splenomegaly [37]. In our study lymphadenopathy and low regulatory T cell number, but not splenomegaly, were related to lower level of naive CD4<sup>+</sup> lymphocytes.

A number of limitations of the study should be acknowledged. Firstly, the results are limited by the small size and heterogeneity of the studied cohort of CVID patients with various clinical manifestations, and patients were not analyzed for monogenic defects associated with CVID. In addition, assessment of the immunological profile in the peripheral blood may not represent the mechanisms generating and sustaining organ-specific chronic inflammation. Furthermore, treatment with low dose of glucocorticoids in some patients, might have had an influence on studied lymphocyte subsets.

## Conclusions

Our findings indicate that the amount of CD8<sup>+</sup> T cells expressing PD-1 is associated with lymphadenopathy and number of regulatory T cells in patients with CVID. Additionally, patients with non-infectious, inflammatory complications have reduced number of peripheral regulatory T cells, depletion of naive CD4<sup>+</sup> T lymphocytes, and higher level of inflammation. Although the implication of our findings for pathogenesis of CVID associated noninfectious complications is not clear, it emphasizes the complexity of immune dysregulation associated with CVID. Additional studies are needed to verify whether regulatory T lymphocytes and PD-1 expression abnormalities contribute to the pathogenesis of CVID associated complications.

## Conflict of interest

None declared.

## Acknowledgments

This work was supported by a research grant from the Jagiellonian University Medical College (grant no. K/ZDS/004588).

## References

1. Bonilla F.A., Barlan I., Chapel H., et al.: International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. *J Allergy Clin Immunol Pract.* 2016; 4 (1): 38–59.
2. Kienzler A.K., Hargreaves C.E., Patel S.Y.: The role of genomics in common variable immunodeficiency. *Clin Exp Immunol.* 2017; 188 (3): 326–332.
3. Boileau J., Mouillot G., Gérard L., et al.: DEFI Study Group. Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study. *J Autoimmun.* 2011; 36 (1): 25.
4. Fischer A., Provot J., Jais J., et al.: Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. *J Allergy Clin Immunol.* 2017; 140 (5): 1388–1393.
5. Tuijnenburg P., Lango Allen H., Burns S.O., et al.: Loss-of-function nuclear factor  $\kappa$ B subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans. *J Allergy Clin Immunol.* 2018; 142: 1285–1296.
6. Warnatz K., Voll R.E.: Pathogenesis of autoimmunity in common variable immunodeficiency. *Front Immunol.* 2012; 3: 210.
7. Azizi G., Abolhassani H., Kiaee F., et al.: Autoimmunity and its association with regulatory T cells and B cell subsets in patients with common variable immunodeficiency. *Allergol Immunopathol (Madr).* 2018; 46 (2): 127–135.
8. Arumugakani G., Wood P.M.D., Carter C.R.D.: Frequency of Treg cells is reduced in CVID patients with autoimmunity and splenomegaly and is associated with expanded CD21low B lymphocytes. *J Clin Immunol.* 2009; 30: 292–300.
9. Azizi G., Mirshafiey A., Abolhassani H., et al.: Circulating Helper T-Cell Subsets and Regulatory T Cells in Patients With Common Variable Immunodeficiency Without Known Monogenic Disease. *J Investig Allergol Clin Immunol.* 2018; 28 (3): 172–181.
10. Yamazaki T., Akiba H., Iwai H., et al.: Expression of programmed death 1 ligands by murine T cells and APC. *J Immunol.* 2002; 169 (10): 5538–5545.
11. Pedoeema A., Azoulay-Alfaguter I., Strazza M., et al.: Programmed death-1 pathway in cancer and autoimmunity. *Clin Immunol.* 2014; 153: 145–152.
12. Bardhan K., Anagnostou T., Boussiotis V.A.: The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. *Front Immunol.* 2016; 7: 550.
13. Ameratunga R., Brewerton M., Slade C., et al.: Comparison of diagnostic criteria for common variable immunodeficiency disorder. *Front Immunol.* 2014; 5: 415.
14. Kuntz M., Goldacker S., Blum H.E., et al.: Analysis of bulk and virus-specific CD8+ T cells reveals advanced differentiation of CD8+ T cells in patients with common variable immunodeficiency. *Clin Immunol.* 2011; 141: 177–186.
15. Barber D.L., Wherry E.J., Masopust D., et al.: Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature.* 2006; 439: 682–687.
16. Duraiswamy J., et al.: Phenotype, function, and gene expression profiles of programmed death-1hi CD8 T cells in healthy human adults. *J Immunol.* 2011; 186: 4200–4212.
17. Wong G.K., Huissoon A.P.: T-cell abnormalities in common variable immunodeficiency: the hidden defect. *J Clin Pathol.* 2016; 69 (8): 672–676.
18. Marashi S.M., Raeiszadeh M., Enright V., et al.: Influence of cytomegalovirus infection on immune cell phenotypes in patients with common variable immunodeficiency. *J Allergy Clin Immunol.* 2012; 129: 1349–1356.
19. Her M., Kim D., Oh M., Jeong H., Choi I.: Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus. *Lupus.* 2009; 18 (6): 501–507.
20. Wang D., Du Q., Luo G., et al.: Aberrant production of soluble inducible T cell co-stimulator and soluble programmed cell death protein 1 in patients with chronic hepatitis B. *Mol Med Rep.* 2017; 16 (6): 8556–8562.

21. Wu H., Miao M., Zhang G., et al.: Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia. *Immunol Invest.* 2009; 38 (5): 408–421.
22. Zhou G., Zhang J., Ren X.W., Hu J.Y., Du G.F., Xu X.Y.: Increased B7-H1 expression on peripheral blood T cells in oral lichen planus correlated with disease severity. *J Clin Immunol.* 2012; 32 (4): 794–801.
23. Sakthivel P., Giscombe R., Ramanujam R., Lefvert A.K.: Polymorphisms in PDCD1 gene are not associated with Wegener's granulomatosis. *Rheumatol Int.* 2009; 29 (10): 1247–1250.
24. Sakthivel P., Ramanujam R., Wang X.B., Pirskanen R., Lefvert A.K.: Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis. *J Neuroimmunol.* 2008; 193 (1–2): 149–155.
25. Chen M.H., Chen W.S., Lee H.T., Tsai T.Y., Chou C.T.: Inverse correlation of programmed death 1 (PD-1) expression in T cells to the spinal radiologic changes in Taiwanese patients with ankylosing spondylitis. *Clin Rheumatol.* 2011; 30: 1181–1187.
26. Petrelli A., Mijnheer G., Hoytema van Konijnenburg D.P., et al.: PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation. *J Clin Invest.* 2018; 128 (10): 4669–4681.
27. de Lollo C., de Moraes Vasconcelos D., da Silva Oliveira L.M., et al.: Impaired CD8(+) T cell responses upon Toll-like receptor activation in common variable immunodeficiency. *J Transl Med.* 2016 May 17; 14 (1): 138.
28. Perreau M., Vigano S., Bellanger F., et al.: Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. *J Exp Med.* 2014; 211 (10): 2033–2045.
29. Wherry E.J., Kurachi M.: Molecular and cellular insights into T cell exhaustion. *Nat Rev Immunol.* 2015; 15 (8): 486–499.
30. Penaloza-MacMaster P., Kamphorst A.O., Wieland A., et al.: Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic CMV infection. *J Exp Med.* 2014; 211 (9): 1905–1918.
31. Carter C.R., Aravind G., Smalle N.L., Cole J.Y., Savic S., Wood P.M.: CVID patients with autoimmunity have elevated T cell expression of granzyme B and HLA-DR and reduced levels of Treg cells. *J Clin Pathol.* 2013; 66 (2): 146–150.
32. Fevang B., Yndestad A., Sandberg W.J., et al.: Low numbers of regulatory T cells in common variable immunodeficiency: association with chronic inflammation in vivo. *Clin Exp Immunol.* 2007; 147 (3): 521–525.
33. Horn J., Manguiat A., Berglund L.J., et al.: Decrease in phenotypic regulatory T cells in subsets of patients with common variable immunodeficiency. *Clin Exp Immunol.* 2009; 156 (3): 446–454.
34. Azizi G., Hafezi N., Mohammadi H., et al.: Abnormality of regulatory T cells in common variable immunodeficiency. *Cell Immunol.* 2017; 315: 11–17.
35. van Amelsfort J.M., Jacobs K.M., Bijlsma J.W., Lafeber F.P., Taams L.S.: CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. *Arthritis Rheum.* 2004; 50 (9): 2775–2785.
36. Hguyen D.X., Ehrenstein M.R.: Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. *J Exp Med.* 2016; 213 (7): 1241–1253.
37. Giovannetti A., Pierdominici M., Mazzetta F., et al.: Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. *J Immunol.* 2007; 178: 3932–3943.
38. Bateman E.A., Ayers L., Sadler R., et al.: T cell phenotypes in patients with common variable immunodeficiency disorders: associations with clinical phenotypes in comparison with other groups with recurrent infections. *Clin Exp Immunol.* 2012; 170 (2): 202–211.